Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Receives $18.25 Consensus Target Price from Analysts

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has received a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $18.25.

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Guggenheim lifted their price objective on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Piper Sandler set a $21.00 price objective on Adaptive Biotechnologies in a report on Friday, February 6th. Finally, BTIG Research upped their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, February 6th.

Adaptive Biotechnologies Price Performance

ADPT opened at $14.43 on Thursday. The stock has a market capitalization of $2.22 billion, a P/E ratio of -36.07 and a beta of 2.19. The company’s 50 day simple moving average is $15.61 and its 200-day simple moving average is $15.93. Adaptive Biotechnologies has a one year low of $6.68 and a one year high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million during the quarter, compared to analysts’ expectations of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. Adaptive Biotechnologies’s revenue was up 51.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.23) EPS. As a group, analysts anticipate that Adaptive Biotechnologies will post -0.92 EPS for the current year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, insider Francis Lo sold 30,593 shares of the stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $14.08, for a total value of $430,749.44. Following the transaction, the insider directly owned 291,374 shares in the company, valued at $4,102,545.92. This represents a 9.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sharon Benzeno sold 63,103 shares of the firm’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $831,066.51. Following the completion of the transaction, the insider directly owned 272,751 shares in the company, valued at approximately $3,592,130.67. The trade was a 18.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 2,422,544 shares of company stock valued at $35,397,620 over the last 90 days. Company insiders own 6.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ameriprise Financial Inc. increased its holdings in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Adaptive Biotechnologies by 303.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after buying an additional 3,299,635 shares during the period. Westfield Capital Management Co. LP bought a new position in Adaptive Biotechnologies during the fourth quarter worth about $65,942,000. Geode Capital Management LLC boosted its holdings in Adaptive Biotechnologies by 3.3% during the fourth quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock worth $57,041,000 after buying an additional 110,825 shares during the last quarter. Finally, State Street Corp grew its position in shares of Adaptive Biotechnologies by 3.3% during the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock worth $51,670,000 after buying an additional 102,362 shares during the period. 99.17% of the stock is currently owned by institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.